CANDEL THERAPEUTICS, INC. Long-Term Debt, Maturity, Year One
CANDEL THERAPEUTICS, INC. (CADL) had Long-Term Debt, Maturity, Year One of $0 as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2026-03-12
- 2025-12-31: Long-Term Debt, Maturity, Year One $0.00.
- 2025-09-30: Long-Term Debt, Maturity, Year One $833.00K.
- 2025-06-30: Long-Term Debt, Maturity, Year One $833.00K.
- 2025-03-31: Long-Term Debt, Maturity, Year One $833.00K.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $833.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $833.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $833.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $10.00M 10-K · filed 2025-03-13 |
| 2024-09-30 | $10.00M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $10.00M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $10.00M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $9.17M 10-K · filed 2024-03-28 |
| 2023-09-30 | $8.87M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $8.87M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $8.87M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |